Gene delivery technologies company SIRION Biotech GmbH reported on Monday revenues of EUR3.1m for its vector design and manufacturing service for the first half of 2020.
This marks a growth of 26% when compared to the same period in 2019.
The company added that the prior year figures have been adjusted for a market approval milestone by one of its licensees.
For the whole of 2020 the company projects revenue of approximately EUR11.0m, which would exceed last year's revenue record.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government